

TrippBio and University of Georgia Research Foundation Expand Licensing Agreement for PanCytoVir™ and Analogs

The revised agreement broadens TrippBio's pipeline with new chemical entities that show promise as broadly active anti-viral treatments

JACKSONVILLE, FL, USA, July 26, 2022 /EINPresswire.com/ -- TrippBio, Inc. (TrippBio), a clinical development-stage biopharmaceutical company developing antiviral treatments and the University of Georgia Research Foundation (UGARF), today announced that they have signed an amendment

to their 21 May 2020 License Agreement expanding cooperation to include additional new chemical entities that have shown promise as broadly active antiviral compounds. Multiple new compounds based on PanCytoVir™ chemistry have been prepared and will be investigated in upcoming preclinical studies. Recent data suggests that PanCytoVir™ and possibly its analogs may be safe and effective therapeutics for other important viral infections including measles, mumps, Dengue, and Zika viruses.

“


This expanded Agreement will allow us to aggressively pursue additional indications and importantly will give us new composition of matter protection for these new indications. ”

Dr. David E. Martin

David E. Martin, PharmD, and CEO of TrippBio, Inc., stated, "We are pleased to extend and expand a very successful collaboration between TrippBio, Inc and Dr. Ralph Tripp of the University of Georgia. This expanded Licensing Agreement will allow us to aggressively pursue these additional indications and importantly will give us new composition of matter protection for these new

indications. We look forward to sharing more on our pipeline expansion in the very near future.”

PanCytoVir™



PanCytoVir™ (formerly known as TD-213) is a repurposed pharmaceutical approved by the FDA for the treatment of the hyperuricemia associated with gout and can be used as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin for prolonging drug plasma levels. PanCytoVir™ is a favorable antiviral drug candidate as it is commercially available and has high plasma concentrations with a benign clinical safety profile. It has demonstrated potent activity against SARS-CoV-2 [1], influenza [2], and RSV [3] in vitro and animal models of infection.

1. Murray J, Hogan RJ, Martin DE, et al. Probenecid potently inhibits SARS-CoV-2 replication in vivo and in vitro. *Scientific Reports* 2021;11;18085 (<https://doi.org/10.1038/s41598-021-97658-w>).
2. Berwitasari O, Yan X, Johnson S et al. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza virus strategy. *Antimicrob Agents Chemother* 57(1), 475-483 (2013).
3. Murray J, Bergeron H, Shepard J, et al. Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. *Viruses* 2022, 14, 912.

About TrippBio, Inc.

TrippBio, Inc. is a Jacksonville, Florida based, clinical development-stage biopharmaceutical company dedicated to commercializing new applications of therapeutics to fight infectious diseases with an emphasis on viral diseases with current efforts focused on identification of drugs to combat infections such as the SARS-CoV-2 virus that causes COVID-19. TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and Professor at the University of Georgia. The University of Georgia Research Foundation is a major shareholder of TrippBio, Inc.

About the University of Georgia

The University of Georgia is the oldest state-chartered institution of higher education in the United States. Spanning more than 750 acres on its main campus alone and employing almost 3,000 faculty members, UGA provides educational and research services to almost 37,000 individuals, including over 8,000 doctoral and professional students. With almost \$500 million in annual research expenditures, and NIH awards totaling more than \$60 million annually, UGA has an estimated \$7.4 billion annual impact on the economy of Georgia. UGA's 18 colleges offer doctoral degrees in 98 areas spanning the liberal arts and humanities; business; journalism; public affairs; law, education, and social work; and include science-based colleges for veterinary medicine, ecology (the first stand-alone college of its type in the world), public health, pharmacy, engineering, and agriculture. The first cohort of medical students was admitted in 2010 to the Augusta University/UGA Medical Partnership, sharing the site of the former Navy Supply Corps School with UGA's College of Public Health in Athens, GA. www.uga.edu.

To learn more, please contact us at info@trippbio.com

Dr. David E. Martin

TrippBio, Inc.

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/582177284>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.